Journal Article
. 2016 Sep;23(4).
doi: 10.1158/1078-0432.CCR-16-1278.

High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial

Torsten O Nielsen 1 Maj-Brit Jensen 2 Samantha Burugu 3 Dongxia Gao 3 Charlotte L Tykjaer Jørgensen 2 Eva Balslev 2 Bent Ejlertsen 2 
  • PMID: 27601592
  •     18 citations


Purpose: Luminal A breast cancers have better prognosis than other molecular subtypes. Luminal A cancers may also be insensitive to adjuvant chemotherapy, although there is little high-level evidence to confirm this concept. The primary hypothesis in this formal prospective-retrospective analysis was to assess interaction between subtype (Luminal A vs. other) and treatment (chemotherapy vs. not) for the primary endpoint (10-year invasive disease-free survival) of a breast cancer trial randomizing women to adjuvant chemotherapy, analyzed in multivariate Cox proportional hazards models using the Wald interaction test.Experimental Design: The Danish Breast Cancer Cooperative Group 77B clinical trial randomized 1,072 premenopausal women to no systematic treatment (control), levamisole, cyclophosphamide, or cyclophosphamide-methotrexate-fluorouracil arms. All arms included radiotherapy but no endocrine therapy. Researchers with no access to clinical data performed intrinsic subtype analysis on tissue microarrays using published immunohistochemical methods based on estrogen receptor, progesterone receptor, HER2, Ki67, and basal markers.Results: Patients (n = 709) had tissue available; chemotherapy benefit in these patients was similar to the original trial (HR, 0.56). Immunohistochemistry classified 165 as Luminal A, 319 Luminal B, 58 HER2-enriched, and 82 core basal (among 91 triple-negative). Patients with Luminal A breast tumors did not benefit from chemotherapy [HR, 1.06; 95% confidence interval (CI), 0.53-2.14; P = 0.86], whereas patients with non-luminal A subtypes did (HR, 0.50; 95% CI, 0.38-0.66; P < 0.001; Pinteraction = 0.048).Conclusions: In a prospective-retrospective analysis of a randomized trial, patients with Luminal A breast cancers did not benefit from adjuvant cyclophosphamide-based chemotherapy. Clin Cancer Res; 23(4); 946-53. ©2016 AACR.

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
Thomas Fleischer, Jovana Klajic, +15 authors, Vessela N Kristensen.
Oncotarget, 2016 Dec 03; 8(1). PMID: 27911866    Free PMC article.
Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.
Joachim Diessner, Manfred Wischnewsky, +8 authors, Achim Wöckel.
PLoS One, 2016 Dec 20; 11(12). PMID: 27992550    Free PMC article.
PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
Nicholas P Tobin, Arian Lundberg, +13 authors, TEX Trialists Group.
Clin Cancer Res, 2017 Oct 04; 23(23). PMID: 28972041    Free PMC article.
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.
Delphine Hequet, Céline Callens, +20 authors, Roman Rouzier.
PLoS One, 2017 Oct 19; 12(10). PMID: 29045452    Free PMC article.
Luminal A Breast Cancer and Molecular Assays: A Review.
Jennifer J Gao, Sandra M Swain.
Oncologist, 2018 Feb 24; 23(5). PMID: 29472313    Free PMC article.
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Maj-Britt Jensen, Anne-Vibeke Lænkholm, +7 authors, Bent Ejlertsen.
Breast Cancer Res, 2018 Jul 29; 20(1). PMID: 30053900    Free PMC article.
Omission of Chemotherapy for the Treatment of Mucinous Breast Cancer: A Nationwide Study from the Korean Breast Cancer Society.
Hyung Suk Kim, Jong Uk Lee, +4 authors, Woo Chan Park.
J Breast Cancer, 2020 Jan 04; 22(4). PMID: 31897333    Free PMC article.
Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.
Clara Taubenhansl, Olaf Ortmann, +2 authors, Monika Klinkhammer-Schalke.
Arch Gynecol Obstet, 2019 Nov 22; 301(2). PMID: 31749031    Free PMC article.
Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Mustapha Abubakar, Jonine Figueroa, +8 authors, Paul D Pharoah.
Mod Pathol, 2019 Apr 13; 32(9). PMID: 30976105    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Cytotoxic Activity of the Mesoionic Compound MIH 2.4Bl in Breast Cancer Cell Lines.
Luciana Amaral de Mascena Costa, Ashlyn C Harmon, +10 authors, J Michael Mathis.
Breast Cancer (Auckl), 2020 Jul 14; 14. PMID: 32655277    Free PMC article.
AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells.
Riley A Hampsch, Jason D Wells, +12 authors, Todd W Miller.
Clin Cancer Res, 2020 Apr 24; 26(14). PMID: 32321715    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity.
Lin He, Yang Lv, Yuhua Song, Biyuan Zhang.
Cancer Manag Res, 2019 Jul 16; 11. PMID: 31303789    Free PMC article.
Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis.
Hong-Fei Gao, Wei-Ping Li, +7 authors, Kun Wang.
Breast, 2020 Sep 19; 54. PMID: 32947149    Free PMC article.
Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer.
Amye J Tevaarwerk, Kari B Wisinski, Ruth M O'Regan.
J Oncol Pract, 2016 Nov 20; 12(11). PMID: 27858538    Free PMC article.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Ulrike Nitz, Oleg Gluz, +18 authors, Nadia Harbeck.
Breast Cancer Res Treat, 2017 Jul 01; 165(3). PMID: 28664507    Free PMC article.
Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis.
Yilun Li, Li Ma.
World J Surg Oncol, 2020 Dec 04; 18(1). PMID: 33267822    Free PMC article.